Activin and Inhibin

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC 50 &gt: 1 μMIn VitroCDK12-IN-E9

CDK4/6-IN-15 is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and